The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity

被引:40
作者
Cancro, M. P. [1 ]
机构
[1] Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA
关键词
D O I
10.1136/ard.2006.058412
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The B lymphocyte stimulator (BLyS; also termed BAFF) family of ligands and receptors plays a central role in B lymphocyte development, selection, and homoeostasis. Members of this family can independently influence different B cell subsets, because the interactions between the two ligands and three receptors vary, and the receptors themselves are differentially expressed among developing, naive, and antigen experienced B cell subsets. These properties prompt careful assessment of how ablative therapies may influence the behaviour of upstream or downstream B lineage populations, as well as how the implementation and expectations of therapeutics targeting BLyS family members must be guided by knowledge of the B cell subsets contributing to pathogenesis.
引用
收藏
页码:34 / 36
页数:3
相关论文
共 38 条
[21]   Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF [J].
Lesley, R ;
Xu, Y ;
Kalled, SL ;
Hess, DM ;
Schwab, SR ;
Shu, HB ;
Cyster, JG .
IMMUNITY, 2004, 20 (04) :441-453
[22]   B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals [J].
Loder, F ;
Mutschler, B ;
Ray, RJ ;
Paige, CJ ;
Sideras, P ;
Torres, R ;
Lamers, MC ;
Carsetti, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (01) :75-89
[23]   BAFF: A fundamental survival factor for B cells [J].
Mackay, F ;
Browning, JL .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (07) :465-475
[24]  
Mackay Fabienne, 2005, V8, P243
[25]  
Melchers F, 2003, ANN RHEUM DIS, V62, P25
[26]   Space, selection, and surveillance: Setting boundaries with BLyS [J].
Miller, Juli P. ;
Stadanlick, Jason E. ;
Cancro, Michael P. .
JOURNAL OF IMMUNOLOGY, 2006, 176 (11) :6405-6410
[27]   BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator [J].
Moore, PA ;
Belvedere, O ;
Orr, A ;
Pieri, K ;
LaFleur, DW ;
Feng, P ;
Soppet, D ;
Charters, M ;
Gentz, R ;
Parmelee, D ;
Li, YL ;
Galperina, O ;
Giri, J ;
Roschke, V ;
Nardelli, B ;
Carrell, J ;
Sosnovtseva, S ;
Greenfield, W ;
Ruben, SM ;
Olsen, HS ;
Fikes, J ;
Hilbert, DM .
SCIENCE, 1999, 285 (5425) :260-263
[28]   B lymphocyte stimulator (BLyS): A therapeutic trichotomy for the treatment of B lymphocyte diseases [J].
Nardelli, B ;
Moore, PA ;
Li, YL ;
Hilbert, DM .
LEUKEMIA & LYMPHOMA, 2002, 43 (07) :1367-1373
[29]   BCMA is essential for the survival of long-lived bone marrow plasma cells [J].
O'Connor, BP ;
Raman, VS ;
Erickson, LD ;
Cook, WJ ;
Weaver, LK ;
Ahonen, C ;
Lin, LL ;
Mantchev, GT ;
Bram, RJ ;
Noelle, RJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (01) :91-97
[30]  
Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO